📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer. (2024)

First Author: Chen L

Attributed to: Development of an effective therapeutic regime for preventing cancer recurrence after surgery using a novel viro-immunotherapeutic agent funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3389/fimmu.2024.1492464

PubMed Identifier: 39840061

Publication URI: http://europepmc.org/abstract/MED/39840061

Type: Journal Article/Review

Volume: 15

Parent Publication: Frontiers in immunology

ISSN: 1664-3224